Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092.

2.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. No abstract available.

PMID:
28835723
3.

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, Coussens LM.

Cell Rep. 2017 Apr 4;19(1):203-217. doi: 10.1016/j.celrep.2017.03.037.

4.

Targeting neoantigens to augment antitumour immunity.

Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM.

Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24. Review. Erratum in: Nat Rev Cancer. 2017 Aug 24;17 (9):569.

5.

Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy.

Lutz ER, Kinkead H, Jaffee EM, Zheng L.

Oncoimmunology. 2014 Dec 21;3(11):e962401. eCollection 2014 Nov.

6.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.

7.

Cancer immunoprevention--the next frontier.

Smit MA, Jaffee EM, Lutz ER.

Cancer Prev Res (Phila). 2014 Nov;7(11):1072-80. doi: 10.1158/1940-6207.CAPR-14-0178. Epub 2014 Sep 22. Review.

8.

A systematic evaluation of websites offering information on chronic kidney disease.

Lutz ER, Costello KL, Jo M, Gilet CA, Hawley JM, Bridgman JC, Song MK.

Nephrol Nurs J. 2014 Jul-Aug;41(4):355-63; 364.

9.

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, Jaffee EM, Zheng L.

Cancer Immunol Res. 2014 Jul;2(7):616-31. doi: 10.1158/2326-6066.CIR-14-0027. Epub 2014 Jun 18.

10.

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Lutz ER, Jaffee EM.

Cancer Immunol Res. 2014 Jun;2(6):518-21. doi: 10.1158/2326-6066.CIR-14-0041. Epub 2014 May 2. Review. No abstract available.

11.

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD.

Blood. 2008 Jan 1;111(1):251-9. Epub 2007 Oct 1.

12.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT.

J Immunol. 2006 Jan 15;176(2):974-83.

13.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM.

J Exp Med. 2004 Aug 2;200(3):297-306.

15.

Watsu-aquatic bodywork.

Lutz ER.

Beginnings. 1999 Mar-Apr;19(2):9, 11. No abstract available.

PMID:
10690023

Supplemental Content

Support Center